MoonLake Immunotherapeutics (MLTX) Revenue & Revenue Breakdown
MoonLake Immunotherapeutics Revenue Highlights
Main Segment (Y)
License
MoonLake Immunotherapeutics Revenue by Period
MoonLake Immunotherapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | - |
MoonLake Immunotherapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
MoonLake Immunotherapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $19.74K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | - |
MoonLake Immunotherapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
MoonLake Immunotherapeutics Revenue Breakdown
MoonLake Immunotherapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 |
|---|---|---|
| License | $299.60M | $299.60M |
MoonLake Immunotherapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 |
|---|---|---|---|---|---|---|
| License | $299.60M | - | $299.60M | $299.60M | $302.10M | $302.10M |
MoonLake Immunotherapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: License (100.00%).
MoonLake Immunotherapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| TVTX | Travere Therapeutics | $145.24M | $54.12M |
| ACLX | Arcellx | $110.32M | $27.38M |
| PLRX | Pliant Therapeutics | $1.58M | - |
| GPCR | Structure Therapeutics | - | - |
| NUVL | Nuvalent | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| AVTE | Aerovate Therapeutics | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| CERE | Cerevel Therapeutics | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| VTYX | Ventyx Biosciences | - | - |
| ETNB | 89bio | - | - |
| AKRO | Akero Therapeutics | - | - |
| ELVN | Enliven Therapeutics | - | - |
| CMPX | Compass Therapeutics | - | - |
| MLTX | MoonLake Immunotherapeutics | - | - |
MLTX Revenue FAQ
What is MoonLake Immunotherapeutics’s yearly revenue?
MoonLake Immunotherapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. MLTX's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is MoonLake Immunotherapeutics’s quarterly revenue?
MoonLake Immunotherapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). MLTX's quarterly revenue for Q4 2023 was $19.74K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is MoonLake Immunotherapeutics’s revenue growth rate?
MoonLake Immunotherapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%
What are MoonLake Immunotherapeutics’s revenue streams?
MoonLake Immunotherapeutics's revenue streams in c 23 are License
What is MoonLake Immunotherapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of MoonLake Immunotherapeutics was License. This segment made a revenue of $299.6M, representing 100.00% of the company's total revenue.